Marketable Securities, Current in USD of UNITED THERAPEUTICS Corp from Q4 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of investment in marketable security, classified as current.
Summary
UNITED THERAPEUTICS Corp quarterly Marketable Securities, Current history and change rate from Q4 2016 to Q3 2025.
  • UNITED THERAPEUTICS Corp Marketable Securities, Current for the quarter ending 30 Sep 2025 was $1.43B, a 19.5% decline year-over-year.
Marketable Securities, Current, Quarterly (USD)
Marketable Securities, Current, YoY Quarterly Change (%)

UNITED THERAPEUTICS Corp Quarterly Marketable Securities, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $1.43B -$345M -19.5% 30 Sep 2025 10-Q 29 Oct 2025
Q2 2025 $1.46B -$160M -9.92% 30 Jun 2025 10-Q 30 Jul 2025
Q1 2025 $1.42B -$34.9M -2.4% 31 Mar 2025 10-Q 30 Apr 2025
Q4 2024 $1.57B -$217M -12.1% 31 Dec 2024 10-Q 29 Oct 2025
Q3 2024 $1.77B +$4.8M +0.27% 30 Sep 2024 10-Q 30 Oct 2024
Q2 2024 $1.62B +$4.1M +0.25% 30 Jun 2024 10-Q 31 Jul 2024
Q1 2024 $1.46B -$244M -14.3% 31 Mar 2024 10-Q 01 May 2024
Q4 2023 $1.79B -$91.1M -4.85% 31 Dec 2023 10-K 26 Feb 2025
Q3 2023 $1.77B +$119M +7.22% 30 Sep 2023 10-Q 01 Nov 2023
Q2 2023 $1.61B +$152M +10.4% 30 Jun 2023 10-Q 02 Aug 2023
Q1 2023 $1.7B +$246M +16.9% 31 Mar 2023 10-Q 03 May 2023
Q4 2022 $1.88B +$842M +81.2% 31 Dec 2022 10-K 21 Feb 2024
Q3 2022 $1.65B +$557M +51% 30 Sep 2022 10-Q 02 Nov 2022
Q2 2022 $1.46B +$435M +42.4% 30 Jun 2022 10-Q 03 Aug 2022
Q1 2022 $1.45B +$555M +61.8% 31 Mar 2022 10-Q 04 May 2022
Q4 2021 $1.04B -$60.4M -5.51% 31 Dec 2021 10-K 22 Feb 2023
Q3 2021 $1.09B +$182M +19.9% 30 Sep 2021 10-Q 03 Nov 2021
Q2 2021 $1.03B +$150M +17.1% 30 Jun 2021 10-Q 04 Aug 2021
Q1 2021 $899M +$230M +34.3% 31 Mar 2021 10-Q 05 May 2021
Q4 2020 $1.1B +$349M +46.7% 31 Dec 2020 10-K 24 Feb 2022
Q3 2020 $910M +$60M +7.06% 30 Sep 2020 10-Q 28 Oct 2020
Q2 2020 $875M -$29.6M -3.27% 30 Jun 2020 10-Q 29 Jul 2020
Q1 2020 $669M -$145M -17.8% 31 Mar 2020 10-Q 29 Apr 2020
Q4 2019 $748M +$800K +0.11% 31 Dec 2019 10-K 24 Feb 2021
Q3 2019 $850M +$269M +46.2% 30 Sep 2019 10-Q 30 Oct 2019
Q2 2019 $905M +$438M +93.7% 30 Jun 2019 10-Q 31 Jul 2019
Q1 2019 $815M +$490M +151% 31 Mar 2019 10-Q 01 May 2019
Q4 2018 $747M +$524M +236% 31 Dec 2018 10-K 26 Feb 2020
Q3 2018 $582M +$438M +306% 30 Sep 2018 10-Q 31 Oct 2018
Q2 2018 $467M +$358M +327% 30 Jun 2018 10-Q 01 Aug 2018
Q1 2018 $324M +$290M +862% 31 Mar 2018 10-Q 02 May 2018
Q4 2017 $222M +$195M +700% 31 Dec 2017 10-K 27 Feb 2019
Q3 2017 $143M 30 Sep 2017 10-Q 25 Oct 2017
Q2 2017 $109M 30 Jun 2017 10-Q 27 Jul 2017
Q1 2017 $33.7M 31 Mar 2017 10-Q 26 Apr 2017
Q4 2016 $27.8M 31 Dec 2016 10-K 21 Feb 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.